Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tanaka, H.
Right arrow Articles by Abe, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tanaka, H.
Right arrow Articles by Abe, S.
(Chest. 2005;128:3717-3723.)
© 2005 American College of Chest Physicians

Prostaglandin E2 Receptor Selective Agonists E-Prostanoid 2 and E-Prostanoid 4 May Have Therapeutic Effects on Ovalbumin-Induced Bronchoconstriction*

Hiroshi Tanaka, MD; Satoshi Kanako, MD and Shosaku Abe, MD

* From the Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.

Correspondence to: Hiroshi Tanaka, MD, Third Departments of Internal Medicine, Sapporo Medical University school of Medicine, South-1, West-16, Chuo-ku, Sapporo, 060-8543, Japan; e-mail: tanakah{at}sapmed.ac.jp

Background: The pharmacologic actions of prostaglandin E2 (PGE2) are mediated through specific E-prostanoid (EP)-1, EP-2, EP-3, and EP-4 receptors. In this study, we determined which PGE2 receptor subtype(s) contribute to the prevention of allergen-induced bronchoconstriction.

Methods: We assessed the effects of these receptor agonists in ovalbumin (OA)-sensitized guinea pigs. The prostaglandin E receptor-subtype agonists tested were ONO-DI-004 (EP-1), ONO-AE1–259 (EP-2), ONO-AE-248 (EP-3), ONO-AE1–329 (EP-4), and sulprostone (EP-1 and EP-3) [Ono Pharmaceutical Company; Osaka, Japan]. We treated the animals with either PGE2 or these agonists 15 min before OA challenge and measured respiratory resistance at 15 min, 1 h, and 3 h.

Results: Allergen-induced bronchoconstriction was significantly (p < 0.01) suppressed at doses > 85 nmol/kg of PGE2. The respiratory resistance elevations 15 min after OA challenge were significantly (p < 0.01) suppressed by preadministration of EP-2 and EP-4 agonists, but airway responsiveness to inhaled methacholine did not improve. EP-1, EP-3, or EP-1/EP-3 agonists had no effect on any parameter.

Conclusions: These results suggest that inhibition of OA-induced bronchoconstriction by PGE2 acts through EP-2 and EP-4 receptors.

Key Words: animal model • asthma • prostaglandin E2 • receptor • smooth muscle






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.